定坤丹用于低预后不孕女性体外受精-胚胎移植的疗效与安全性:多中心双盲随机安慰剂对照试验方案
约15%育龄夫妇受不孕影响,卵巢储备减退或卵巢低反应女性需行体外受精-胚胎移植,但促性腺激素反应不佳。中国两项近期临床研究提示定坤丹可提高此类患者临床妊娠率,但研究异质性无法定论。本研究为多中心双盲随机安慰剂对照试验,拟纳入460例患者,比较定坤丹与安慰剂对妊娠结局的影响。
要点
- 定坤丹可能为低预后行IVF-ET女性提供临床解决方案。
- 目前尚无西药可改善此类患者IVF-ET的妊娠结局。
- 需设计良好的随机试验确定定坤丹的疗效。
核心结论
- 定坤丹可能改善低预后不孕女性IVF-ET的临床妊娠结局,但需本试验验证。
研究设计与样本
- 多中心、双盲、随机安慰剂对照试验,从中国12家公立医院招募460例不孕患者。
- 患者按1:1随机分为定坤丹组或安慰剂组,均采用GnRH拮抗剂方案,卵巢刺激5周,随访6个月记录妊娠结局。
关键数值与推荐
- 主要结局为比较定坤丹组与安慰剂组的妊娠结局。
- 次要结局包括获卵总数、胚胎质量、移植日内膜厚度、着床率和早期流产率。
临床怎么用
- 定坤丹可能作为低预后女性IVF-ET的辅助治疗选择,但当前证据尚不充分。
局限性
- 现有研究存在异质性,无法对定坤丹疗效得出明确结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 15% of couples in the reproductive age are affected by infertility. Women with diminished ovarian reserves (DOR) or with a poor ovarian response (POR) are required to undergo in vitro fertilization and embryo transfer (IVF-ET) to achieve pregnancy. However, studies indicate that poor response to gonadotropin stimulation has been reported in women undergoing IVF-ET. Results from two recent clinical studies in China suggest that traditional Chinese medicine (TCM) formula Dingkun pill (DKP) showed a curative effect by improving the clinical pregnancy rate in women with DOR and POR. However, the heterogeneity of the studies does not allow one to draw a definitive conclusion on the therapeutic effect of DKP. Therefore, the purpose of this study was to investigate the effect of DKP on improving the clinical outcome of pregnancy of IVF-ET in women with low prognosis. METHODS: A multicenter, double-blinded, randomized placebo-controlled trial was conducted. A total of 460 infertile patients undergoing IVF or intracytoplasmic sperm injection (ICSI) were recruited from 12 public hospitals in China. Participants were randomly divided into the experimental group (DKP formula) or the placebo group (control) at a ratio of 1:1. All patients were treated with GnRH antagonist protocol and ovarian stimulation performed for 5 weeks (from the 5th day of the previous menstrual cycle to the day of oocyte retrieval). The patients were followed up for 6 months to record their conception outcome. The primary outcome is to compare the pregnancy outcome to those under placebo treatment. Secondary outcomes included the total count of the retrieved oocyte, embryo quality, endometrial thickness on ET day, implantation rate, and early miscarriage rate. DISCUSSION: Currently, no multicenter, double-blind, randomized, placebo-controlled trials have been performed on the use of the DKP formula to improve on the clinical outcome of the conception of IVF-ET in women with low prognosis. DKP might provide a good clinical solution for females with low prognosis and undergoing IVF. There is no contemporary Western medicine to improve on the clinical outcome of conception in IVF-ET in women with low prognosis. Therefore, it is important to undertake a well-designed randomized trial to determine the effect of DKP in improving the clinical outcome of the conception of IVF-ET in women with low prognosis. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR). TRIAL REGISTRATION NUMBER: ChiCTR1900026614. Registered on 16 October 2019.
引用
- Song J, Ma T, Liang Y, et al. Efficacy and safety of Dingkun pill for female infertility patients with low prognosis undergoing in vitro fertilization-embryo transfer: study protocol for a multicenter, double-blind, randomized, placebo-controlled trial. Trials. 2020. PMID: 32560734. doi:10.1186/s13063-020-04502-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。